CompletedInterventionalPhase 3Updated Aug 17, 2012
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension | NCT00293761 | Trialant
CompletedInterventionalPhase 3Updated Nov 18, 2016
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
ClinicalTrials.gov ID
NCT00293761
Lead Sponsor
Alcon ResearchINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
109Actual
Last Update Posted
Nov 18, 2016Estimated
Start Date
Jan 2006
Primary Completion Date
May 2006Actual
Completion Date
May 2006Actual
Brief Summary
The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
Open-angle Glaucoma
Ocular Hypertension
Travoprost, Investigational
Travoprost (TRAVATAN)
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients of either sex of any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension.
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
Under age 18.
Other protocol-defined exclusion criteria may apply.